Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 16, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 205,000 ordinary shares of 25 pence each.
- Purchase Price: 1,459.7217 pence per share.
- Treasury Shares Held: 200,341,678 shares (post-transaction).
- Shares in Issue: 5,786,307,713 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on October 16, 2006, pursuant to shareholder authority granted at the Annual General Meeting on May 17, 2006. The purchased shares are intended to be held in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the repurchase by multiplying the 205,000 shares by the price of 1,459.7217 pence.
- Confirm the updated total share capital structure (5,786,307,713 issued shares plus 200,341,678 treasury shares).
- Review the May 17, 2006 Annual General Meeting minutes to understand the full scope of the share buyback authority utilized.